Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
– Established a transformative collaboration with Vertex to discover and develop intracellular Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1 –
Related news for (TRDA)
- Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
- Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
- Entrada Therapeutics Reports First Quarter 2025 Financial Results
- Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
- Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44